Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 1, 2017. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
- Issued Share Capital (as of August 31, 2017): 5,371,728,234 ordinary shares of 25 pence each.
- Treasury Shares: 453,205,950 ordinary shares.
- Total Voting Rights: 4,918,522,284.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period regarding financial performance or operational metrics. It only states the current capital structure as of August 31, 2017.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory notification intended to assist shareholders in calculating notification thresholds under the Financial Conduct Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (4,918,522,284) to determine if disclosure thresholds for shareholding interests have been met.
- Confirm the number of shares held in Treasury (453,205,950) when calculating the denominator for ownership percentage.
- Note that this filing does not contain financial performance data; refer to the Company's Form 20-F or interim reports for revenue and profit metrics.